




Cite this: *Chem. Commun.*, 2018, 54, 10371

Received 21st June 2018,  
Accepted 17th July 2018

DOI: 10.1039/c8cc04954h

rsc.li/chemcomm


# Development and cellular application of visible-light-controllable HNO releasers based on caged Piloty's acid†

Mitsuyasu Kawaguchi, Takuma Tani, Ryoma Hombu, Naoya Ieda and Hidehiko Nakagawa \*

**Nitroxyl (HNO) is a gaseous molecule with unique pharmacological functions distinct from those of nitric oxide. Because HNO is highly reactive with biological molecules, spatiotemporally controllable HNO releasers are required. Herein, we report the first visible-light-controllable HNO releasers, based on caged Piloty's acid, and we demonstrate their applicability in living cells.**

Nitroxyl (HNO), a type of reactive nitrogen species (RNS) and the one-electron-reduced form of nitric oxide, was reported by Angeli *et al.* in the latter half of the 19th century.<sup>1</sup> In recent years, HNO has attracted attention due to its unique pharmacological activity, such as enhancement of cardiac contractility,<sup>2</sup> and it is considered a therapeutic candidate for cardiovascular disease and cancer.<sup>3</sup> However, the precise roles of HNO *in vivo* are still not well understood, because HNO has very high reactivity with biological thiols ( $k = 7.6 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ ),<sup>4</sup> phosphine ( $k = 8.4 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ ) and metal-containing proteins,<sup>5</sup> and spontaneously dimerizes to generate  $\text{N}_2\text{O}$  ( $k = 8 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ ) in aqueous solution.<sup>6</sup> Many HNO donors, such as Angeli's salt ( $\text{Na}_2\text{N}_2\text{O}_3$ , **AS**),<sup>7</sup> Piloty's acid derivatives,<sup>8</sup> diazeniumdiolates (NONOates),<sup>9</sup> acyl nitroso compounds,<sup>10</sup> and acyloxy nitroso compounds<sup>11</sup> have been developed and used in biological studies, but they all decompose spontaneously to release HNO under physiological conditions. In order to control HNO release more precisely, photocontrollable HNO donors have been developed by our group based on a retro Diels–Alder reaction<sup>12</sup> and by Sampson's group based on *N*-alkoxy-sulfonamide bearing a *O*-(3-hydroxy-2-naphthalenyl)-methyl (HNM) photolabile protecting group (PPG).<sup>13</sup> However, these compounds are not suitable for cellular experiments, because HNO release is triggered by ultraviolet (UV) irradiation, which is cytotoxic.

Herein, we aimed to develop HNO donors that are photocontrollable by irradiation in the visible light range, that would be applicable in living cells. For this purpose, we focused on



**Scheme 1** (a) Piloty's acid spontaneously releases HNO under basic conditions. (b) Piloty's acid derivatives bearing  $-\text{NO}_2$  (compound **A**) or  $-\text{Br}$  (compound **B**) at the *ortho* position can spontaneously release HNO under physiological neutral conditions due to their low  $\text{pK}_a$  values compared to Piloty's acid. (c) Photocontrollable HNO releasers (**8**, **9**) release HNO in a photoirradiation-dependent manner in the visible light region (400–430 nm) under physiological conditions.

Piloty's acid, which releases HNO *via* deprotonation of its hydroxyl group under basic conditions (Scheme 1a).<sup>8</sup> Furthermore, its derivatives, 2-nitro-*N*-hydroxybenzensulfonamide (compound **A**) and 2-bromo-*N*-hydroxybenzensulfonamide (compound **B**) release HNO even under physiological conditions ( $\text{pH} \approx 7.4$ ) (Scheme 1b).<sup>8c</sup> Based on these reports, we designed and synthesized compounds **8** and **9**, in which the hydroxyl group is protected by a (7-diethylaminocoumarin-4-yl)methyl group, a kind of PPG releasable by visible light near 400 nm (Scheme 1c).<sup>14</sup> By using an HNO selective fluorescence probe, **P-Rhod**,<sup>15</sup> we show that these HNO donors enable visible-light-controllable HNO release in living cells without cytotoxicity.


Compounds **8** and **9** were synthesized as shown in Scheme 2. Briefly, Riley oxidation and hydride reduction of 7-diethylamino-4-methylcoumarin (**1**) gave the hydroxymethyl derivative

Graduate School of Pharmaceutical Sciences, Nagoya City University,  
3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan.

E-mail: deco@phar.nagoya-cu.ac.jp

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8cc04954h





Scheme 2 Synthesis of HNO releaser compounds **8** and **9**.

(**3**) in two steps. Next, (7-diethylaminocoumarin-4-yl)methyl bromide (**5**) was synthesized by mesylation and bromination of compound **3**.  $\text{S}_{\text{N}}2$  reaction converted **5** to Boc-protected aminooxylated compound **6**, which was deprotected with HCl to yield **7**. Condensation reaction with benzenesulfonyl chloride derivatives afforded compounds **8** and **9**, whose structures were confirmed by NMR, MS, and elemental analysis.

The UV-vis spectrum of a solution of compound **8** or **9** in MilliQ water showed strong absorption around 400 nm derived from the coumarin moiety (Fig. S1, ESI<sup>†</sup>). Therefore, we decided to use a Xe lamp source equipped with a 400–430 nm band pass filter for photodecomposition.

Next, we examined the photodecomposition reaction of compound **8** by means of HPLC (Fig. 1a–e). After photoirradiation, compound **8** ( $t_{\text{R}} = 17.9$  min) completely disappeared and new peaks were detected. Among them, two were assigned to 2-nitrobenzene sulfonic acid (compound **11**) ( $t_{\text{R}} = 2.8$  min) and 7-diethylamino-4-hydroxymethylcoumarin (compound **3**) ( $t_{\text{R}} = 7.6$  min); these were expected to be generated after HNO release. However, the peak of compound **3** was much smaller than expected, and an unexpected peak ( $t_{\text{R}} = 12.5$  min) was observed as the main peak. We purified the eluate corresponding to this peak, and identified the product as 7-diethylaminocoumarin-4-carbaldehyde oxime (compound **12**) by examination of the NMR spectrum. We also separately synthesized compound **12** and confirmed that the authentic compound was identical with the photodecomposition product on the basis of NMR and HPLC analyses (Scheme S1 and Fig. S2, ESI<sup>†</sup>). These results suggest that the main photodecomposition mechanism is not the expected one (path I). Instead, we propose a mechanism (path II) in which compound **12** is mainly generated (Fig. 1f). After photoirradiation, the C–O bond at the coumarinyl 4-position is decomposed by heterolytic cleavage (or homolytic cleavage followed by one electron transfer) and a new C–N bond is formed by nucleophilic attack of an adjacent nitrogen atom. Then sulfonic acid, compound **11**, is detached and compound **12** is formed through tautomerization of the nitroso compound. We estimated a fraction of path I from the result of Fig. 1, whose path releases HNO, and found that 7.2% of compound **8** underwent path I reaction (Fig. S3, ESI<sup>†</sup>).

Fortunately, this decomposition process does not generate any gaseous or HNO-related small molecules, but instead affords





Fig. 1 Photodecomposition of compound **8** was monitored by HPLC. (a) compound **8**, (b) compound **8** upon photoirradiation (10 min, 20  $\text{mW cm}^{-2}$ ), (c) compound **11**, (d) compound **3**, (e) compound **12**. \* We could not identify the structure of this product. In all chromatograms, absorption at 254 nm was monitored. (f) Expected photodecomposition mechanism of compound **8** (path I) and putative (path II) photodecomposition mechanism of compound **8** to afford the unexpected oxime compound **12**.

2-nitrosulfinic acid, a common co-product with the HNO-releasing pathway (Fig. 1f). Although the expected product was a minor one, we next examined HNO release by means of GC-MS analysis of  $\text{N}_2\text{O}$  formation *via* dimerization of HNO. As shown in Fig. 2, the mass chromatogram revealed the formation of  $\text{N}_2\text{O}$  from Angeli's salt (**AS**) (Fig. 2b) or after visible light irradiation (20  $\text{mW cm}^{-2}$ , 20 min) of an aqueous solution of compound **8** (Fig. 2d and f). In the absence of photoirradiation, this peak was not observed, indicating that compound **8** is stable and does not release HNO in the absence of photoirradiation under ambient conditions (Fig. 2c). Under the same conditions, compound **9** did not give an apparent  $\text{N}_2\text{O}$  peak (Fig. 2e and f). These results indicate that compound **8** releases HNO more efficiently than compound **9**, reflecting a previous finding that 2-nitro-*N*-hydroxybenzenesulfonamide has higher HNO-releasing ability than 2-bromo-*N*-hydroxybenzenesulfonamide.<sup>8c</sup> Thus, the HNO-releasing abilities of compounds **8** and **9** appear to depend on the property of the Piloty's acid derivatives themselves.

Next, to further confirm HNO production from our photocontrollable HNO donors, we used the HNO-specific fluorescence probe, **P-Rhod**,<sup>15</sup> which employs a Staudinger-like reaction for HNO detection. A fluorescence increment was observed only when an aqueous solution containing compound **8** and **P-Rhod** was photoirradiated (22  $\text{mW cm}^{-2}$  for 10 min; Fig. 2g). In contrast, the fluorescence increment was suppressed in the presence of 2-mercaptoethanol (2-ME), an HNO scavenger. In addition, in the case of compound **9**, a smaller fluorescence increment was observed, which is consistent with the GC-MS analyses (Fig. 2a–f). We also examined the irradiation time-dependency of HNO generation and found that compound **8**





**Fig. 2** (a)  $\text{N}_2\text{O}$  formation from compound **8**. GC-MS detection of  $\text{N}_2\text{O}$  formation: (b) from **AS**, (c) from compound **8** in the dark or (d) upon photoirradiation (20 min,  $20 \text{ mW cm}^{-2}$ ), and (e) from compound **9** upon photoirradiation. (f) Integration of the  $\text{N}_2\text{O}$  peak ( $m/z$  44). The results are mean  $\pm$  S.D. ( $n = 3$ ). (g) Detection of HNO generation using **P-Rhod**. Compound **8** or **9** ( $10 \mu\text{M}$ ) was photoirradiated (10 min,  $22 \text{ mW cm}^{-2}$ ) in the presence of **P-Rhod**. **AS** ( $10 \mu\text{M}$ ) was used as a positive control and 2-ME ( $14 \text{ mM}$ ) as a HNO scavenger. (h) Irradiation time-dependency of HNO generation. **P-Rhod** ( $10 \mu\text{M}$ ) and compound **8** ( $10 \mu\text{M}$ ) were photo-irradiated ( $22 \text{ mW cm}^{-2}$ ) for 0, 1, 2, 5, or 10 minutes. The results are mean  $\pm$  S.D. ( $n = 3$ ). NS = not significant,  $*P \leq 0.05$ ,  $**P \leq 0.01$ ,  $***P \leq 0.001$  (one-way ANOVA with Bonferroni correction).


released HNO in a time-dependent manner (Fig. 2h). From this result, we speculated that the HNO releasing from compound **8** upon photoirradiation is slow enough to be detected with **P-Rhod** and most of released HNO were detected by **P-Rhod**.

In addition, the results in Fig. 2 indicate that  $10 \mu\text{M}$  compound **8** released 44% of the amount of HNO released by  $10 \mu\text{M}$  Angeli's salt (**AS**), meaning that compound **8** would release  $4.4 \mu\text{M}$  HNO, suggesting moderate efficiency. However, this calculation may not be accurate, because **AS** releases almost all the HNO molecules in water at once, so it is possible that not all the released HNO can react with **P-Rhod** due to the extremely high reaction rate of HNO dimerization; *i.e.*, a significant amount of dimerization to form  $\text{N}_2\text{O}$  may occur, reducing the fluorescence increment with **P-Rhod**. Therefore, the actual concentration of HNO generated from  $10 \mu\text{M}$  compound **8** is likely to be less than  $4.4 \mu\text{M}$ . Thus, we examined HNO formation from compound **8** upon photoirradiation by means of LC-MS analysis. In this analysis, we detected  $N,N'$ -diacetyl-L-cystine formation *via* reaction between excess  $N$ -acetylcysteine (NAC) and HNO, because it is known that thiols react quickly with HNO to afford two products, sulfinamide and disulfide compounds (Fig. S4, ESI†).<sup>16</sup> We found that  $100 \mu\text{M}$  compound **8** released an amount of HNO that corresponded to the HNO formation from  $16 \mu\text{M}$  **AS**. Thus, although the total amount of HNO released from compound **8** was smaller than that from **AS**, these results confirm that compound **8** can release HNO gradually depending on photoirradiation time (Fig. 2h), which seems consistent with the putative biological actions of HNO. Although endogenous HNO sources have not been elucidated, the reaction

of NO and  $\text{H}_2\text{S}$  has drawn attention as a potential candidate for HNO formation.<sup>17</sup> Because these gaseous molecules, NO and  $\text{H}_2\text{S}$ , are enzymatically produced in biological systems, HNO seems to be generated gradually through the chemical reaction between NO and  $\text{H}_2\text{S}$  and may work as a signaling molecule. In contrast, a significant amount of HNO generated from **AS** dimerizes, and thus cannot work as a signaling molecule.

To examine whether compound **8** releases HNO *in cellulo* upon photoirradiation, we first checked its cell-membrane permeability and subcellular localization. Compound **8** was found to be membrane-permeable, and was mainly localized to endoplasmic reticulum (ER), as judged from the result of co-staining with ER-Tracker Green<sup>®</sup>; the Manders' overlap coefficient was calculated to be 0.990 (Fig. S5, ESI†). We next treated HEK293T cells (RIKEN Cell Bank, RCB2202) with compound **8** and **P-Rhod**, and irradiated the cells with visible light ( $400\text{--}430 \text{ nm}$ ,  $20 \text{ mW cm}^{-2}$ ) for 30 min. Fluorescence intensity was found to be increased in the irradiated cells, as observed by fluorescence microscopy (Fig. 3). In the absence of compound **8**, on the other hand, slight fluorescence was observed even after photoirradiation. These results suggest that compound **8** can release HNO *in cellulo*. Finally, we examined the cytotoxicity and stability of compound **8** in cellular systems and found that compound **8** was almost non-cytotoxic at up to  $32 \mu\text{M}$  (Fig. S6, ESI†) and was completely stable in DMEM containing 5% FBS for at least 24 h in the dark (Fig. S7, ESI†).

In summary, we have designed and synthesized the first nitroxyl (HNO) releasers controllable with visible light ( $400\text{--}430 \text{ nm}$ ), based on caged Piloty's acid. Although the photodecomposition reaction did not follow the expected path, we demonstrated that the compounds work as photocontrollable HNO releasers and we clarified the actual mechanism of decomposition. Even though HNO is very unstable, we were able to confirm HNO release from compound **8** upon photoirradiation *in vitro* and *in cellulo* by means of GC-MS analysis, and by employing an HNO-specific fluorescence probe, **P-Rhod**. Thus, compound **8** is the first photocontrollable HNO releaser that is applicable in living cells, and we anticipate that it will become indispensable for future biological studies of HNO.



**Fig. 3** Fluorescence images of HEK293T cells treated with **P-Rhod** ( $1 \mu\text{M}$ ) in the presence or absence of compound **8** ( $20 \mu\text{M}$ ) upon photoirradiation ( $400\text{--}430 \text{ nm}$ ) for 30 minutes. (a and d) DIC images of cells treated with **P-Rhod** in the presence or absence of compound **8**, respectively. (b and c) Fluorescence images of cells treated with compound **8** and **P-Rhod** after and before photoirradiation, respectively. (e) Fluorescence image of cells treated with **P-Rhod** after photoirradiation without compound **8**.



We thank all the members of H. N.'s laboratory. This work was supported in part by JSPS KAKENHI Grant Number 26893223, 15K18899 (M. K.) and 16H05103 (H. N.), as well as by a grant-in-aid for Scientific Research on Innovative Areas from MEXT (26111012, H. N.) and a grant from Daiichi Sankyo Foundation of Life Science (H. N.).

## Conflicts of interest

There are no conflicts to declare.

## Notes and references

- (a) J. M. Fukuto, C. H. Switzer, K. M. Miranda and D. A. Wink, *Annu. Rev. Pharmacol. Toxicol.*, 2005, **45**, 335–355; (b) J. C. Irvine, R. H. Ritchie, J. L. Favalaro, K. L. Andrew, R. E. Widdop and B. K. Kemp-Harper, *Trends Pharmacol. Sci.*, 2008, **29**, 601–608; (c) J. M. Fukuto, C. L. Bianco and T. A. Chavez, *Free Radical Biol. Med.*, 2009, **47**, 1318–1324; (d) B. K. Kemp-Harper, *Antioxid. Redox Signaling*, 2011, **14**, 1609–1613.
- (a) W. D. Gao, C. I. Murray, Y. Tian, X. Zhong, J. F. Dumond, X. Shen, B. A. Stanley, D. B. Foster, D. A. Wink, S. B. King, J. E. Van Eyk and N. Paolocci, *Circ. Res.*, 2012, **111**, 1002–1011; (b) E. Cheong, V. Tumbe, J. Abramson, G. Salama and D. A. Stoyanovsky, *Cell Calcium*, 2005, **37**, 87–96; (c) C. G. Tocchetti, W. Wang, J. P. Froehlich, S. Huke, M. A. Aon, G. M. Wilson, G. Di Benedetto, B. O'Rourke, W. D. Gao, D. A. Wink, J. P. Toscano, M. Zaccolo, D. M. Bers, H. H. Valdivia, H. Cheng, D. A. Kass and N. Paolocci, *Circ. Res.*, 2007, **100**, 96–104.
- (a) J. A. Norris, M. R. Santippour, M. Lu, T. Park, J. Y. Rao and M. I. Jackson, *Int. J. Cancer*, 2008, **122**, 1905–1910; (b) N. Paolocci, I. Jackson, B. E. Lopez, K. M. Miranda, C. G. Tocchetti, D. A. Wink, A. J. Hobbs and J. M. Fukuto, *Pharmacol. Ther.*, 2007, **113**, 442–458; (c) C. H. Switzer, W. Flores-Santana, D. Mancardi, S. Donzelli, D. Basudhar, L. A. Ridnour, K. M. Miranda, J. M. Fukuto, N. Paolocci and D. A. Wink, *Biochim. Biophys. Acta, Bioenerg.*, 2009, **1787**, 835–840.
- M. I. Jackson, T. H. Han, L. Serbulea, A. Dutton, E. Ford, K. M. Miranda, K. N. Houk, D. A. Wink and J. M. Fukuto, *Free Radical Biol. Med.*, 2009, **47**, 1130–1139.
- (a) J. A. Reisz, E. Bechtold and S. B. King, *Dalton Trans.*, 2010, **39**, 5203–5212; (b) D. A. Bazylnski and T. C. Hollocher, *J. Am. Chem. Soc.*, 1985, **107**, 7982–7986; (c) A. C. Montenegro, V. T. Amorebieta, L. D. Slep, D. F. Martin, F. Roncaroli, D. H. Murgida, S. E. Bari and J. A. Olabe, *Angew. Chem., Int. Ed.*, 2009, **48**, 4213–4216.
- (a) D. A. Bazylnski and T. C. Hollocher, *Inorg. Chem.*, 1985, **24**, 4285–4288; (b) V. Shafirovich and S. V. Lyman, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 7340–7345.
- A. Angeli, *Gazz. Chim. Ital.*, 1896, **26**, 17.
- (a) O. Piloty, *Ber. Dtsch. Chem. Ges.*, 1896, **29**, 1559; (b) M. R. Cline, C. Tu, D. N. Silverman and J. P. Toscano, *Free Radical Biol. Med.*, 2011, **50**, 1274–1279; (c) K. Izawa, H. Nakagawa, K. Matsuo, K. Kawai, N. Ieda, T. Suzuki and N. Miyata, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 2340–2343.
- (a) K. M. Miranda, T. Katori, C. L. Torres de Holding, L. Thomas, L. A. Rindnour, W. J. McLendon, S. M. Cologna, A. S. Dutton, H. C. Champion, D. Mancardi, C. G. Tocchetti, J. E. Saavedra, L. K. Keefer, K. N. Houk, J. M. Fukuto, D. A. Kass, N. Paolocci and D. A. Wink, *J. Med. Chem.*, 2005, **48**, 8220–8228; (b) L. K. Keefer, *ACS Chem. Biol.*, 2011, **6**, 1147–1155.
- (a) R. N. Atkinson, B. M. Storey and S. B. King, *Tetrahedron Lett.*, 1996, **37**, 9287–9290; (b) Y. Xu, M. M. Alavanya, V. L. Johnson, G. Yasaki and S. B. King, *Tetrahedron Lett.*, 2000, **41**, 4265–4269; (c) B. B. Zeng, J. Huang, M. W. Wright and S. B. King, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 5565–5568.
- X. Sha, T. S. Isbell, R. P. Patel, C. S. Day and S. B. King, *J. Am. Chem. Soc.*, 2006, **128**, 9687–9692.
- (a) Y. Adachi, H. Nakagawa, K. Matsuo, T. Suzuki and N. Miyata, *Chem. Commun.*, 2008, 5149–5151; (b) K. Matsuo, H. Nakagawa, Y. Adachi, E. Kameda, H. Tsumoto, T. Suzuki and N. Miyata, *Chem. Commun.*, 2010, **46**, 3788–3790; (c) H. Nakagawa, *Nitric oxide*, 2011, **25**, 195–200; (d) H. Nakagawa, *J. Inorg. Biochem.*, 2013, **118**, 187–190.
- Y. Zhou, R. B. Cink, R. S. Dassanayake, A. J. Seed, N. E. Brasch and P. Sampson, *Angew. Chem., Int. Ed.*, 2016, **55**, 13229–13232.
- (a) T. Eckardt, V. Hagen, B. Schade, R. Schmidt, C. Schweitzer and J. Bendig, *J. Org. Chem.*, 2002, **67**, 703–710; (b) N. Ieda, S. Yamada, M. Kawaguchi, N. Miyata and H. Nakagawa, *Bioorg. Med. Chem.*, 2016, **24**, 2789–2793.
- K. Kawai, N. Ieda, K. Aizawa, T. Suzuki, N. Miyata and H. Nakagawa, *J. Am. Chem. Soc.*, 2013, **135**, 12690–12696.
- W. D. Gao, C. I. Murray, Y. Tian, X. Zhong, J. F. DuMond, X. Shen, B. A. Stanley, D. B. Foster, D. A. Wink, S. B. King, J. E. Van Eyk and N. Paolocci, *Circ. Res.*, 2012, **111**, 1002–1011.
- Z. Miao and S. B. King, *Nitric oxide*, 2016, **57**, 1–14.

